Optional Read But Promoting CYDY, from yahoo finan
Post# of 148170
(Total Views: 771)
Posted On: 03/09/2021 4:41:17 PM
Optional Read But Promoting CYDY, from yahoo finance CYDY
Another Review....
Long & Holding
WHY WOULD ANYONE SELL NOW???
There is no better time to invest in a biopharma then the situation that has been presented to CYDY RIGHT NOW! IMHO!
What is the situation? CYDY now has the data and information that EVERY biopharma wants to know when they are working with a drug and trying to figure out where this works best and for whom. The CD12 trial has clearly outlined the path forward. I have been in the Medical Device space for 29 years and investing in the BioPharma space for about 20 + years. There is never a straight ride up in development of a drug. There are start and stops and A LOT of uncertainty when developing a drug. But, CYDY has arrived at that place of certainty with Leronlimab. Don't get me wrong the science and it's MOA has been known by CYDY and other notable physicians (ex: Dr. Patterson), but the application of that science in COVID is now ready to take us to where we thought we would be by now. It is just going be delayed until June.
As so many REAL TRUTHFUL posters have said already; there is a BOAT LOAD of opportunities/catalysts to increase the value of our investments:
1) Any day Philippines will begin to order LL...thats Revenue
2) CLEARLY heard NP state: putting together the application for a conditional EUA for COVID Critical using data from CD12
3) While submitting the conditional EUA for COVID Critical. They will move forward with the new CD16 trial of a 140 patients. This is plan B, if the application of the conditional EUA does not pass. Plus, provides a pathway for BLA submission and full approval for COVID Critical
4) MHRA is going to look at the 46 patients from the Open Label. MHRA may issue their own version of the EUA and approve sales of LL...thats revenue
5) Canada is somewhat similar
6) They are exploring Brazil
7) HIV BLA to be SUBMITTED to many countries regulatory agencies. In the U.S. once FDA receives the BLA, they generally set a PDUFA date approximately six months out.NP estimated approval before end of year with REVENUE
LONG HAULER Phase 2 study will be done and results known probably in April setting up the metrics for phase 3
9) NASH is rolling along and this has big potential.
10) CANCER: apparently the early results on TUMORs is so overwhelmingly encouraging that the CONSENSUS is that CYDY will be a oncology company.
So I say to my fellow investors.....REALLY you're selling now?
Another Review....
Long & Holding
WHY WOULD ANYONE SELL NOW???
There is no better time to invest in a biopharma then the situation that has been presented to CYDY RIGHT NOW! IMHO!
What is the situation? CYDY now has the data and information that EVERY biopharma wants to know when they are working with a drug and trying to figure out where this works best and for whom. The CD12 trial has clearly outlined the path forward. I have been in the Medical Device space for 29 years and investing in the BioPharma space for about 20 + years. There is never a straight ride up in development of a drug. There are start and stops and A LOT of uncertainty when developing a drug. But, CYDY has arrived at that place of certainty with Leronlimab. Don't get me wrong the science and it's MOA has been known by CYDY and other notable physicians (ex: Dr. Patterson), but the application of that science in COVID is now ready to take us to where we thought we would be by now. It is just going be delayed until June.
As so many REAL TRUTHFUL posters have said already; there is a BOAT LOAD of opportunities/catalysts to increase the value of our investments:
1) Any day Philippines will begin to order LL...thats Revenue
2) CLEARLY heard NP state: putting together the application for a conditional EUA for COVID Critical using data from CD12
3) While submitting the conditional EUA for COVID Critical. They will move forward with the new CD16 trial of a 140 patients. This is plan B, if the application of the conditional EUA does not pass. Plus, provides a pathway for BLA submission and full approval for COVID Critical
4) MHRA is going to look at the 46 patients from the Open Label. MHRA may issue their own version of the EUA and approve sales of LL...thats revenue
5) Canada is somewhat similar
6) They are exploring Brazil
7) HIV BLA to be SUBMITTED to many countries regulatory agencies. In the U.S. once FDA receives the BLA, they generally set a PDUFA date approximately six months out.NP estimated approval before end of year with REVENUE
LONG HAULER Phase 2 study will be done and results known probably in April setting up the metrics for phase 3 9) NASH is rolling along and this has big potential.
10) CANCER: apparently the early results on TUMORs is so overwhelmingly encouraging that the CONSENSUS is that CYDY will be a oncology company.
So I say to my fellow investors.....REALLY you're selling now?
(6)
(1)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼